Aleix Prat (A Prat)

ResearcherID Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 74

Top Venues

NPJ breast cancer

Nature communications

Cancers

Clinical cancer research : an official journal of the American Association for Cancer Research

Solti

Universitat Autonoma de Barcelona Facultat de Medicina (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Solti Jun 01 2019

Spain

President

Institut d'Investigacions Biomèdiques August Pi i Sunyer Dec 01 2015

Spain

Representative :: Oncology and Haematology Research Area Num. 5.

IDIBAPS

Spain

Principal Investigator and Research Director Team Translational Genomics and Targeted Therapeutics in Solid Tumors

Universitat de Barcelona Facultat de Medicina Oct 01 2014

Spain

Associate Professor :: Medicine Department

Hospital Clínic de Barcelona Jul 18 2014

Spain

Head of Medical Oncology Department

National Evaluation and Foresight Agency (ANEP) Spanish Ministry of Science and Innovation. Jan 01 2014

Spain

Evaluator of project proposals

Vall d’Hebron Institute of Oncology (VHIO). Hospital Universitari de la Vall d’Hebron , Barcelona, Spain

Spain

Principal Investigator Translational Genomics Group

Universitat Autònoma de Barcelona Jan 01 2011 - Jun 15 2013

Spain

Ph.D. Program of Medicine :: Medicine

Vall d’Hebron Institute of Oncology (VHIO)/ Hospital Universitari de la Vall d’Hebron, Barcelona, Spain

Spain

Part-time research position

University of North Carolina Lineberger Comprehensive Cancer Center

United States

Postdoctoral Research Associate. Charles M. Perou Laboratory.

Centro Nacional de Investigaciones Oncológicas

Spain

Master in Molecular Oncology. Third Edition. Grade: Honors

Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Spain

Spain

Medical Oncology Fellowship, Department of Medical Oncology. Program Drector: José Baselga, MD.

American Association for Cancer Research

United States

Workshop in Molecular Biology in Clinical Oncology.

Mayo Clinic Cancer Center

United States

Clinical Clerkship :: Hematology/Oncology

Education History

Universitat Autonoma de Barcelona Facultat de Medicina Oct 01 2012 - Oct 01 2013

Spain

PHD

Publications

Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist 29 (5) (2024)
Antonio Llombart, José Pérez-García, Fara Brasó-Maristany, Laia Paré, Guillermo Villacampa, Maria Gion, Peter Schmid, Marco Colleoni, Manuel Ruiz Borrego, Patricia Galván, Joel S Parker, Wesley Buckingham, Charles M Perou, Patricia Villagrasa, Jose Antonio Guerrero, Miguel Sampayo, Mario Mancino, Aleix Prat, Javier Cortes
HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M Perou
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ breast cancer 10 (1) (2024)
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M Perou
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ breast cancer 10 (1) (2024)
Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist (2024)
Marta García de Herreros, Juan Carlos Laguna, Joan Padrosa, Tanny Daniela Barreto, Manoli Chicote, Carme Font, Ignacio Grafiá, Lucía Llavata, Elia Seguí, Albert Tuca Rodríguez, Margarita Viladot, Carles Zamora-Martínez, Sara Fernández-Méndez, Adrián Téllez, Josep Maria Nicolás, Aleix Prat, Pedro Castro-Rebollo, Javier Marco-Hernandez
Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment. Diagnostics (Basel, Switzerland) 14 (7) (2024)
Francesco Schettini, Eva Blondeaux, Chiara Molinelli, Raphaëlle Bas, Hee Jeong Kim, Antonio di Meglio, Rinat Bernstein Molho, Sabine C Linn, Katarzyna Pogoda, Estela Carrasco, Kevin Punie, Elisa Agostinetto, Nerea Lopetegui Lia, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Marion Acheritogaray, Alberta Ferrari, Shani Paluch-Shimon, Robert Fruscio, Wanda Cui, Stephanie M Wong, Claudio Vernieri, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Cynthia Villarreal Garza, De Marchis Laura, Fabio Puglisi, Leonor Vasconcelos de Matos, Monica Mariño, Luis Teixeira, Rossella Graffeo, Alessia Rognone, Alessandra Chirco, Nicoleta Antone, Yara G Abdou, Maximilian Marhold, Ivana Božović-Spasojević, Cortes Salgado Alfonso, Luca Carmisciano, Marco Bruzzone, Curigliano Giuseppe, Aleix Prat, Matteo Lambertini
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer (2024)
Leonard Schmiester, Fara Brasó-Maristany, Blanca Gonzalez-Farre, Tomás Pascual, Joaquín Gavilá, Xavier Tekpli, Jürgen Geisler, Vessela N Kristensen, Arnoldo Frigessi, Aleix Prat, Alvaro Köhn-Luque
Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (17) (2024)
Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist 29 (5) (2024)
Adrienne G Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortes, Sara M Tolaney, Aleix Prat
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nature reviews. Clinical oncology (2024)
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M Perou
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ breast cancer 10 (1) (2024)
Irene Andreu-Saumell, Alba Rodriguez-Garcia, Vanessa Mühlgrabner, Marta Gimenez-Alejandre, Berta Marzal, Joan Castellsagué, Fara Brasó-Maristany, Hugo Calderon, Laura Angelats, Salut Colell, Mara Nuding, Marta Soria-Castellano, Paula Barbao, Aleix Prat, Alvaro Urbano-Ispizua, Johannes B Huppa, Sonia Guedan
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition. Nature communications 15 (1) (2024)
Francesco Schettini, Eva Blondeaux, Chiara Molinelli, Raphaëlle Bas, Hee Jeong Kim, Antonio di Meglio, Rinat Bernstein Molho, Sabine C Linn, Katarzyna Pogoda, Estela Carrasco, Kevin Punie, Elisa Agostinetto, Nerea Lopetegui Lia, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Marion Acheritogaray, Alberta Ferrari, Shani Paluch-Shimon, Robert Fruscio, Wanda Cui, Stephanie M Wong, Claudio Vernieri, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Cynthia Villarreal Garza, De Marchis Laura, Fabio Puglisi, Leonor Vasconcelos de Matos, Monica Mariño, Luis Teixeira, Rossella Graffeo, Alessia Rognone, Alessandra Chirco, Nicoleta Antone, Yara G Abdou, Maximilian Marhold, Ivana Božović-Spasojević, Cortes Salgado Alfonso, Luca Carmisciano, Marco Bruzzone, Curigliano Giuseppe, Aleix Prat, Matteo Lambertini
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer 130 (16) (2024)
Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist 29 (5) (2024)
Irene Andreu-Saumell, Alba Rodriguez-Garcia, Vanessa Mühlgrabner, Marta Gimenez-Alejandre, Berta Marzal, Joan Castellsagué, Fara Brasó-Maristany, Hugo Calderon, Laura Angelats, Salut Colell, Mara Nuding, Marta Soria-Castellano, Paula Barbao, Aleix Prat, Alvaro Urbano-Ispizua, Johannes B Huppa, Sonia Guedan
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition. Nature communications 15 (1) (2024)
Marta García de Herreros, Juan Carlos Laguna, Joan Padrosa, Tanny Daniela Barreto, Manoli Chicote, Carme Font, Ignacio Grafiá, Lucía Llavata, Elia Seguí, Albert Tuca Rodríguez, Margarita Viladot, Carles Zamora-Martínez, Sara Fernández-Méndez, Adrián Téllez, Josep Maria Nicolás, Aleix Prat, Pedro Castro-Rebollo, Javier Marco-Hernandez
Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment. Diagnostics (Basel, Switzerland) 14 (7) (2024)
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Marta García de Herreros, Juan Carlos Laguna, Joan Padrosa, Tanny Daniela Barreto, Manoli Chicote, Carme Font, Ignacio Grafiá, Lucía Llavata, Elia Seguí, Albert Tuca Rodríguez, Margarita Viladot, Carles Zamora-Martínez, Sara Fernández-Méndez, Adrián Téllez, Josep Maria Nicolás, Aleix Prat, Pedro Castro-Rebollo, Javier Marco-Hernandez
Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment. Diagnostics (Basel, Switzerland) 14 (7) (2024)
Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist 29 (5) (2024)
Leonard Schmiester, Fara Brasó-Maristany, Blanca Gonzalez-Farre, Tomás Pascual, Joaquín Gavilá, Xavier Tekpli, Jürgen Geisler, Vessela N Kristensen, Arnoldo Frigessi, Aleix Prat, Alvaro Köhn-Luque
Computational model predicts patient outcomes in Luminal B breast cancer treated with endocrine therapy and CDK4/6 inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M Perou
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ breast cancer 10 (1) (2024)
Irene Andreu-Saumell, Alba Rodriguez-Garcia, Vanessa Mühlgrabner, Marta Gimenez-Alejandre, Berta Marzal, Joan Castellsagué, Fara Brasó-Maristany, Hugo Calderon, Laura Angelats, Salut Colell, Mara Nuding, Marta Soria-Castellano, Paula Barbao, Aleix Prat, Alvaro Urbano-Ispizua, Johannes B Huppa, Sonia Guedan
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition. Nature communications 15 (1) (2024)
Elia Seguí, Juan Manuel Torres, Edouard Auclin, David Casadevall, Sara Peiro Carmona, Juan Aguilar, Marta García de Herreros, Teresa Gorría, Juan Carlos Laguna, Marta Rodríguez, Azucena González, Nicolas Epaillard, Javier Gavira, Victor Bolaño, Jose Carlos Tapia, Marco Tagliamento, Cristina Teixidó, Hugo Arasanz, Sara Pilotto, Rafael López-Castro, Xabier Mielgo-Rubio, Cristina Urbano, Gonzalo Recondo, Mar Diaz Pavon, Maria Virginia Bluthgen, José Nicolas Minatta, Lorena Lupinacci, Fara Brasó-Maristany, Aleix Prat, Alexandru Vlagea, Laura Mezquita
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease. Cancers 16 (17) (2024)
Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, Tomás Pascual, Laia Paré, Julia Maues, Patricia Galván, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martínez-Sáez, Mercedes Marín-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Esther Sanfeliu, Blanca González, Ana Vivancos, Patricia Villagrasa, Joel S Parker, Charles M Perou, PierFranco Conte, Aleix Prat, Valentina Guarneri
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. Journal of the National Cancer Institute 115 (3) (2023)
Aleix Prat, Fara Brasó-Maristany, Adrienne G Waks, Esther Sanfeliu, Youli Xia, Meritxell Bellet-Ezquerra, Patricia Galván, Débora Martínez, Tomás Pascual, Mercedes Marín-Aguilera, Anna Rodríguez, Nuria Chic, Barbara Adamo, Laia Paré, María Jesús Vidal Losada, Mireia Margelí, Ester Ballana, Marina Gómez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sánchez-Bayona, Anna Suñol, Cristina Saura, Eva Ciruelos, P Tolosa Ortega, Montserrat Muñoz, Blanca González-Farré, Patricia Villagrasa, Joel S Parker, Charles M Perou, Ana Vivancos
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature communications 14 (1) (2023)
Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, Tomás Pascual, Laia Paré, Julia Maues, Patricia Galván, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martínez-Sáez, Mercedes Marín-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Esther Sanfeliu, Blanca González, Ana Vivancos, Patricia Villagrasa, Joel S Parker, Charles M Perou, PierFranco Conte, Aleix Prat, Valentina Guarneri
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. Journal of the National Cancer Institute 115 (3) (2023)
Aleix Prat, Fara Brasó-Maristany, Adrienne G Waks, Esther Sanfeliu, Youli Xia, Meritxell Bellet-Ezquerra, Patricia Galván, Débora Martínez, Tomás Pascual, Mercedes Marín-Aguilera, Anna Rodríguez, Nuria Chic, Barbara Adamo, Laia Paré, María Jesús Vidal Losada, Mireia Margelí, Ester Ballana, Marina Gómez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sánchez-Bayona, Anna Suñol, Cristina Saura, Eva Ciruelos, P Tolosa Ortega, Montserrat Muñoz, Blanca González-Farré, Patricia Villagrasa, Joel S Parker, Charles M Perou, Ana Vivancos
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature communications 14 (1) (2023)
Curigliano Giuseppe, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. NPJ breast cancer 9 (1) (2023)
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Nicholas Wang, Tomás Pascual, Pier Selenica, Katherine Sanchez, Hiroaki Nitta, Monesh Kapadia, Anne C Pavlick, Patricia Galván, Brent N Rexer, Andres Forero-Torres, Rita Nanda, Anna Maria V Storniolo, Ian E Krop, Matthew P Goetz, Julie R Nangia, Antonio C Wolff, Jorge S Reis-Filho, Jorge Sergio Reis-Filho, Susan G Hilsenbeck, Aleix Prat, C Kent Osborne, Rachel Schiff, Mothaffar F Rimawi
A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Curigliano Giuseppe, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. NPJ breast cancer 9 (1) (2023)
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, María Jesús Vidal Losada, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos Henrique Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ breast cancer 9 (1) (2023)
Aleix Prat, Fara Brasó-Maristany, Adrienne G Waks, Esther Sanfeliu, Youli Xia, Meritxell Bellet-Ezquerra, Patricia Galván, Débora Martínez, Tomás Pascual, Mercedes Marín-Aguilera, Anna Rodríguez, Nuria Chic, Barbara Adamo, Laia Paré, María Jesús Vidal Losada, Mireia Margelí, Ester Ballana, Marina Gómez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sánchez-Bayona, Anna Suñol, Cristina Saura, Eva Ciruelos, P Tolosa Ortega, Montserrat Muñoz, Blanca González-Farré, Patricia Villagrasa, Joel S Parker, Charles M Perou, Ana Vivancos
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature communications 14 (1) (2023)
Aleix Prat, Nadia Solovieff, Fabrice Andre, Joyce O'Shaughnessy, David A Cameron, Wolfgang Janni, Gabe S Sonke, Yoon Sim Yap, Denise A Yardley, Ann H Partridge, Astrid Thuerigen, Juan Pablo Zarate, Agnes Lteif, Fei Su, Lisa Anne Carey
Intrinsic subtype and overall survival of patients with advanced HR+/HER2- breast cancer treated with ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Benedetta Conte, Luca Boni, Giancarlo Bisagni, Antonio Durando, Giovanni Sanna, Stefania Gori, Ornella Garrone, Stefano Tamberi, Sabino De Placido, Francesco Schettini, Antonio Pazzola, Riccardo Ponzone, Filippo Montemurro, Gianluigi Lunardi, Rosario Notaro, Maria De Angioletti, Anna Turletti, Mauro Mansutti, Fabio Puglisi, Antonio Frassoldati, Mauro Porpiglia, Alessandra Fabi, Daniele Generali, Giovanni Scognamiglio, Maura Rossi, Fara Brasó-Maristany, Aleix Prat, Barbara Cardinali, Patrizia Piccioli, Martina Serra, Sonia Lastraioli, Claudia Bighin, Francesca Poggio, Matteo Lambertini, Lucia Del Mastro
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, Tomás Pascual, Laia Paré, Julia Maues, Patricia Galván, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martínez-Sáez, Mercedes Marín-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Esther Sanfeliu, Blanca González, Ana Vivancos, Patricia Villagrasa, Joel S Parker, Charles M Perou, PierFranco Conte, Aleix Prat, Valentina Guarneri
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. Journal of the National Cancer Institute 115 (3) (2023)
Curigliano Giuseppe, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. NPJ breast cancer 9 (1) (2023)
Aleix Prat, Fara Brasó-Maristany, Adrienne G Waks, Esther Sanfeliu, Youli Xia, Meritxell Bellet-Ezquerra, Patricia Galván, Débora Martínez, Tomás Pascual, Mercedes Marín-Aguilera, Anna Rodríguez, Nuria Chic, Barbara Adamo, Laia Paré, María Jesús Vidal Losada, Mireia Margelí, Ester Ballana, Marina Gómez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sánchez-Bayona, Anna Suñol, Cristina Saura, Eva Ciruelos, P Tolosa Ortega, Montserrat Muñoz, Blanca González-Farré, Patricia Villagrasa, Joel S Parker, Charles M Perou, Ana Vivancos
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature communications 14 (1) (2023)
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, María Jesús Vidal Losada, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos Henrique Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ breast cancer 9 (1) (2023)
Alessio Cortellini, Juan Aguilar-Company, Ramon Salazar, Mark Bower, Ailsa Sita-Lumsden, Andrea Plaja, Alvin J X Lee, Alexia Bertuzzi, Carlo Tondini, Nikolaos Diamantis, Clara Martinez-Vila, Aleix Prat, Eleanor Apthorp, Alessandra Gennari, David James Pinato
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer. British journal of cancer 127 (10) (2022)
Aleix Prat, Luis G Paz-Ares, Manel Juan, Enriqueta Felip Font, Elena Garralda, Blanca Gonzalez-Farre, Ana M Arance, Juan Martín-Liberal, Joaquín Gavilá, Ana López-González, Juan Miguel Cejalvo, Yann Izarzugaza, Kepa Amillano, Javier García Corbacho, Cristina Saura, Fabricio Racca, Cinta Hierro, Esther Sanfeliu, Xavier Gonzalez, Jordi Canes, Guillermo Villacampa, Fernando Salvador, Tomás Pascual, Ricard Mesía, Andres Cervantes, Josep Tabernero
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future oncology (London, England) (2022)
Sara Lahoz, Adela Rodríguez, Laia Fernández, Teresa Gorría, Reinaldo Moreno, Francis Esposito, Helena Oliveres, Santiago Albiol, Tamara Saurí, David Pesantez, Gisela Riu, Miriam Cuatrecasas, Pedro Jares, Leire Pedrosa, Estela Pineda Losada, Antonio Postigo, Antoni Castells, Aleix Prat, Joan Maurel, Jordi Camps
Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53 -Mutated Metastatic Colorectal Cancer. Cancers 14 (23) (2022)
Sara Lahoz, Adela Rodríguez, Laia Fernández, Teresa Gorría, Reinaldo Moreno, Francis Esposito, Helena Oliveres, Santiago Albiol, Tamara Saurí, David Pesantez, Gisela Riu, Miriam Cuatrecasas, Pedro Jares, Leire Pedrosa, Estela Pineda Losada, Antonio Postigo, Antoni Castells, Aleix Prat, Joan Maurel, Jordi Camps
Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53 -Mutated Metastatic Colorectal Cancer. Cancers 14 (23) (2022)
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Nuria Lopez-Bigas, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández-Losa, Faye Su, Kui Lin, Robert B Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C Turner, Aleix Prat, Paolo G Nuciforo, Rodrigo Dienstmann, Chandra S Verma, Núria López-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nature communications 13 (1) (2022)
Sara Lahoz, Adela Rodríguez, Laia Fernández, Teresa Gorría, Reinaldo Moreno, Francis Esposito, Helena Oliveres, Santiago Albiol, Tamara Saurí, David Pesantez, Gisela Riu, Miriam Cuatrecasas, Pedro Jares, Leire Pedrosa, Estela Pineda Losada, Antonio Postigo, Antoni Castells, Aleix Prat, Joan Maurel, Jordi Camps
Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53 -Mutated Metastatic Colorectal Cancer. Cancers 14 (23) (2022)
Natalia Jiménez, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Albert Font, Alejo Rodriguez-Vida, Miguel Ángel Climent, Sara Cros, Isabel Chirivella, Montserrat Domenech, Mariona Figols, Enrique González-Billalabeitia, Daniel Jiménez Peralta, Leonardo Rodríguez-Carunchio, Samuel García-Esteve, Marta Garcia de Herreros, Maria J Ribal, Aleix Prat, Begona Mellado
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel. Cancers 14 (19) (2022)
Francesco Schettini, Fara Brasó-Maristany, Nicole M Kuderer, Aleix Prat
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes. NPJ breast cancer 8 (1) (2022)
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Sherko Kuemmel, Mohammad Parsa Mohammadian, Daniel Gebauer, Ronald Kates, Laia Paré, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktaş, Claudia Schumacher, Rachel Wuerstlein, Monika Gräser, Enrico Pelz, Katarzyna Jóźwiak, Christine Zu Eulenburg, Hans Heinrich Kreipe, Nadia Harbeck, null null
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (22) (2022)
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Nuria Lopez-Bigas, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández-Losa, Faye Su, Kui Lin, Robert B Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C Turner, Aleix Prat, Paolo G Nuciforo, Rodrigo Dienstmann, Chandra S Verma, Núria López-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nature communications 13 (1) (2022)
Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Pusztai, Mothaffar F Rimawi, Rachel Schiff, Grazia Arpino, Sabino De Placido, Aleix Prat, Daniele Generali
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers 13 (6) (2021)
Mercedes Marín-Aguilera, María V Pereira, Natalia Jiménez, Òscar Reig, Anna Cuartero, Iván Victoria, Caterina Aversa, Laura Ferrer-Mileo, Aleix Prat, Begona Mellado
Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes. Cancers 13 (19) (2021)
Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, Maria Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrasa, Núria Chic, María Jesús Vidal Losada, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, PierFranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa Anne Carey, Charles M Perou, Aleix Prat
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (11) (2021)
Gaia Griguolo, Garazi Serna, Tomás Pascual, R Fasani, X Guardia, N Chic, L Paré, S Pernas, M Muñoz, Mafalda Oliveira, María Jesús Vidal Losada, A Llombart-Cussac, J Cortés, P Galván, B Bermejo, N Martínez, R López, Serafin Morales Murillo, I Garau, Luis Manso Sanchez, J Alarcón, E Martínez, P Villagrasa, Aleix Prat, Paolo G Nuciforo
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ precision oncology 5 (1) (2021)
Olga Martínez-Sáez, Tomás Pascual, Fara Brasó-Maristany, Nuria Chic, Blanca González-Farré, Esther Sanfeliu, Adela Rodríguez, Débora Martínez, Patricia Galván, Anna Belén Rodríguez, Francesco Schettini, Benedetta Conte, María Jesús Vidal Losada, Barbara Adamo, Antonio Martinez-Pozo, Montserrat Muñoz, Reinaldo Moreno, Patricia Villagrasa, Fernando Salvador, Eva M Ciruelos, Iris Faull, Justin I Odegaard, Aleix Prat
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. NPJ breast cancer 7 (1) (2021)
Yoo Jane Han, Jing Zhang, Jung-Hyun Lee, Jennifer M Mason, Olga Karginova, Toshio F Yoshimatsu, Qinyu Hao, Ian Hurley, Laia Paré Brunet, Aleix Prat, Kannanganattu V Prasanth, Michaela U Gack, Olufunmilayo I Olopade
The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. Cancer research 81 (6) (2021)
Richard Buus, Zsolt Szijgyarto, Eugene F Schuster, Hui Xiao, Ben P Haynes, Ivana Sestak, Jack Cuzick, Laia Paré, Elia Seguí, Nuria Chic, Aleix Prat, Mitchell Dowsett, Maggie Chon U Cheang
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®. NPJ breast cancer 7 (1) (2021)
Nuria Chic, Fara Brasó-Maristany, Aleix Prat
Biomarkers of immunotherapy response in breast cancer beyond PD-L1. Breast cancer research and treatment (2021)
Leticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, Daniel Guimarães Tiezzi, Guillermo Villacampa, Samuel Gonçalves-Ribeiro, Laia Paré, Carla Anjos Souza, Vanesa Ortega, Stephen-John Sammut, Pol Cusco, Roberta Fasani, Suet-Feung Chin, Jose Perez-Garcia, Rodrigo Dienstmann, Paolo Nuciforo, Patricia Villagrasa, Isabel T Rubio, Aleix Prat, Carlos Caldas
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. NPJ breast cancer 7 (1) (2021)
Helga Bergholtz, Jodi M Carter, Alessandra Cesano, Maggie Chon U Cheang, Sarah E Church, Prajan Divakar, Christopher A Fuhrman, Shom Goel, Jingjing Gong, Jennifer L Guerriero, Margaret L Hoang, E Shelley Hwang, Hellen Kuasne, Jinho Lee, Yan Liang, Elizabeth A Mittendorf, Jessica Perez, Aleix Prat, Lajos Pusztai, Jason W Reeves, Yasser Riazalhosseini, Jennifer K Richer, Özgür Sahin, Hiromi Sato, Ilana Schlam, Therese Sørlie, Daniel G Stover, Sandra M Swain, Alexander Swarbrick, E Aubrey Thompson, Sara M Tolaney, Sarah E Warren, null On Behalf Of The GeoMx Breast Cancer Consortium
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler. Cancers 13 (17) (2021)
Fara Brasó-Maristany, Laia Paré, Nuria Chic, Olga Martínez-Sáez, Tomás Pascual, Meritxell Mallafré-Larrosa, Francesco Schettini, Blanca González-Farré, Esther Sanfeliu, Débora Martínez, Patricia Galván, Esther Barnadas, Belinda Salinas, Pablo Tolosa, Eva Ciruelos, Esther Carcelero, Cecilia Guillén, Barbara Adamo, Reinaldo Moreno, Maria Vidal, Montserrat Muñoz, Aleix Prat
Gene expression profiles of breast cancer metastasis according to organ site. Molecular oncology (2021)
Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Brasó-Maristany, Zighereda Ogbah, Mireia Parés, Marta Guzmán, Judit Grueso, Olga Rodríguez, Mafalda Oliveira, Analía Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, Aleix Prat, Rodrigo Dienstmann, Paolo G Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Gaia Griguolo, Maria Vittoria Dieci, Laia Paré, Federica Miglietta, Daniele Giulio Generali, Antonio Frassoldati, Luigi Cavanna, Giancarlo Bisagni, Francesco Giotta, Enrico Tagliafico, Katia Cagossi, Guido Ficarra, Aleix Prat, Pierfranco Conte, Valentina Guarneri
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. NPJ breast cancer 7 (1) (2021)
Tomás Pascual, Mafalda Oliveira, Patricia Villagrasa, Vanesa Ortega, Laia Paré, Begoña Bermejo, Serafin Morales Murillo, Kepa Amillano, Rafael López, Patricia Galván, Jordi Canes, Fernando Salvador, Paolo Nuciforo, Isabel T Rubio, Antonio Llombart-Cussac, Serena Di Cosimo, José Baselga, Nadia Harbeck, Aleix Prat, Javier Cortes
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. NPJ breast cancer 7 (1) (2021)
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, María Jesús Vidal Losada, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos Henrique Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ breast cancer 7 (1) (2021)
Gaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, Tomás Pascual, Núria Chic, Tamara Saurí, Ronald Kates, Oleg Gluz, Débora Martínez, Laia Paré, Vassilena Tsvetkova, David Pesantez, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Patricia Galván, Laura Barberá, Miriam Cuatrecasas, Mathias Christgen, Hans Kreipe, Inés Monge-Escartín, Patricia Villagrasa, Dolors Soy, Tommaso Giarratano, Maria Vittoria Dieci, PierFranco Conte, Nadia Harbeck, Valentina Guarneri, Aleix Prat
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers 12 (7) (2020)
Aleix Prat, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, María Jesús Vidal Losada, Fara Brasó-Maristany, Patricia Galván, Jan Christoph Brase, Vanessa Rodrik-Outmezguine, Stephen Johnston, Eva Ciruelos Gil, Joel S Parker
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (23) (2020)
David J Pinato, Alvin J X Lee, Federica Biello, Elia Seguí, Juan Aguilar-Company, Anna Carbó, Riccardo Bruna, Mark Bower, Gianpiero Rizzo, Sarah Benafif, Carme Carmona, Neha Chopra, Claudia Andrea Cruz, Francesca D'Avanzo, Joanne S Evans, Myria Galazi, Isabel Garcia-Fructuoso, Alessia Dalla Pria, Thomas Newsom-Davis, Diego Ottaviani, Andrea Patriarca, Roxana Reyes, Rachel Sharkey, Christopher C T Sng, Yien Ning Sophia Wong, Daniela Ferrante, Lorenza Scotti, Gian Carlo Avanzi, Mattia Bellan, Luigi Mario Castello, Javier Marco-Hernández, Meritxell Mollà, Mario Pirisi, Isabel Ruiz-Camps, Pier Paolo Sainaghi, Gianluca Gaidano, Joan Brunet, Josep Tabernero, Aleix Prat, Alessandra Gennari
Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers 12 (7) (2020)
Eva Ciruelos Gil, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escriva-de-Romani, Luis Manso Sanchez, Barbara Adamo, E Martínez de Dueñas, Javier Cortes, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Alvaro Montaño, Begoña Bermejo, Serafin Morales Murillo, María J Echarri, Estela Vega, Blanca Gonzalez-Farre, Patricia Galván, Jordi Canes, Paolo G Nuciforo, Xavier Gonzalez, Aleix Prat
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (22) (2020)
Natascha Hruschka, Jorge Ferrer, Maria Subijana, Osvaldo Graña-Castro, Francisco Del Caño-Ochoa, Laia Paré Brunet, Igor Chernukhin, Ana Sagrera, Aurelien De Reynies, Bernhard Kloesch, Suet-Feung Chin, Octavio Burgués, David Andreu, Begoña Bermejo, Juan Miguel Cejalvo, Joe Sutton, Carlos Caldas, Santiago Ramón-Maiques, Jason S Carroll, Aleix Prat, Francisco X Real, Paola Martinelli
The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Oncogene 39 (32) (2020)
Elba Marin, Cristina Teixidó, Elena Carmona-Rocha, Roxana Reyes, Ainara Arcocha, Nuria Viñolas, MªCarmen Rodríguez-Mues, Carlos Cabrera, Marcelo Sánchez, Ivan Vollmer, Sergi Castillo, Silvia Muñoz, Ivana G Sullivan, Adela Rodriguez, Mireia Garcia, Silvia Alos, Pedro Jares, Antonio Martinez-Pozo, Aleix Prat, Miguel Ángel Molina-Vila, Noemi Reguart
Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. Cancers 12 (5) (2020)
Tomás Pascual, Juan M Cejalvo, Mafalda Oliveira, Maria Vidal, Estela Vega, Sergi Ganau, Ana Julve, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Luis de la Cruz-Merino, Manel Juan, Juan M Ferrero-Cafiero, Jordi Canes, Xavier Gonzalez, Patricia Villagrasa, Aleix Prat
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future oncology (London, England) 16 (24) (2020)
Joaquín Gavilá, Mafalda Oliveira, Tomás Pascual, Jose Perez-Garcia, Xavier Gonzàlez, Jordi Canes, Laia Paré, Isabel Calvo, Eva Ciruelos, Montserrat Muñoz, Juan A Virizuela, Isabel Ruiz, Raquel Andrés, Antonia Perelló, Jerónimo Martínez, Serafín Morales, Mercedes Marín-Aguilera, Débora Martínez, Juan C Quero, Antonio Llombart-Cussac, Aleix Prat
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. BMC medicine 17 (1) (2019)
Aleix Prat, J S Parker
Standardized versus research-based PAM50 intrinsic subtyping of breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 22 (6) (2019)

Aleix Prat.css-eqlu8i{font-size:small;padding-left:4px;} (A Prat)

Publication Activity (10 Years)

Top Topics

Top Venues

Aleix Prat (A Prat)